Lilly’s Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

Novartis study validates need for better migraine treatment, as Novartis-Amgen drug hits market

  While Novartis and Amgen work to keep up with pent-up demand for their newly launched migraine treatment Aimovig, a new study backed by both pharma companies looks at real-world needs of migraine patients. The first data released from the “My Migraine Voice” survey, initiated and funded by Novartis and the European Migraine and Headache Alliance and … Συνεχίστε να διαβάζετε Novartis study validates need for better migraine treatment, as Novartis-Amgen drug hits market.